For decades, the mutation driving more than 90% of pancreatic cancer cases was considered simply undruggable. Scientists knew exactly what was killing people. They just couldn't stop it. On Wednesday, the FDA approved a pill that does exactly that, and patients taking it nearly doubled their survival time compared to chemotherapy.
The Cancer That's Been Winning for Decades
Pancreatic cancer is a specific kind of ruthless. The American Cancer Society estimates about 67,000 new cases will be diagnosed in the United States this year alone, and more than 52,000 people will die from it. The five-year survival rate sits at 13%. Thirteen percent. That's not a typo.
The disease is so lethal largely because it's nearly invisible until it's already spreading. By the time most patients get diagnosed, they're out of good options. Treatment has historically come down to chemotherapy regimens that are brutal, marginally effective, and have changed little in decades.
The core biological problem has been a mutation in the Ras gene family, specifically what are known as Kras mutations, which act like a stuck accelerator for tumor growth. Researchers have known about this driver for years. The issue was a structural quirk in the mutated protein that made it almost impossible for drugs to bind to it. The scientific consensus for a long time was essentially: we see the problem, we cannot touch it.
The Molecular Glue Nobody Thought Would Work
Revolution Medicines, a biotech company based in Redwood City, California, found a way around it. Their drug, daraxonrasib, uses what The Guardian describes as essentially a molecular glue to bind with multiple Kras subtypes simultaneously. It's a first-of-its-kind approach to a problem that stymied the industry for generations.
The FDA approved the drug under the brand name Rasonque, and it's taken as a daily pill. In a company-funded study of 500 patients whose metastatic cancer had already stopped responding to prior treatment, those taking daraxonrasib lived a median of 13.2 months. The chemotherapy group managed 6.7 months. Nearly double the survival time, with fewer severe side effects on top of it.
The FDA signed off on it more than six months ahead of their original target date, which tells you something about how they read the data. 'It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,' acting FDA commissioner Kyle Diamantas said in a statement.
From 60 Minutes to Official Approval
The drug had already attracted unusual public attention before Wednesday's announcement. Former Nebraska senator Ben Sasse appeared on CBS's 60 Minutes earlier this year and described experiencing less pain while taking the drug as part of its trial. That broadcast triggered a wave of public interest that was significant enough to prompt the FDA to allow expanded access before official approval for patients who met certain criteria.
That's a meaningful data point about how this drug has been received. Expanded access programs exist, but the FDA doesn't throw them open casually. The agency was clearly watching the same numbers the rest of the medical world was watching.
Revolution Medicines isn't stopping at pancreatic cancer either. According to The Guardian, the company is now studying its Kras-targeting technology against other cancers, including lung cancer. The same mutation that drives pancreatic tumors shows up in other cancers too. If the molecular glue approach holds up elsewhere, the implications go well beyond one disease.
What Doctors Are Actually Saying
Oncologists who treat pancreatic cancer are expressing cautious but genuine optimism, which is notable in a field that has learned the hard way not to get too excited too quickly. The Guardian reports that doctors believe this approval could open a door to more new treatments, with dozens of experimental drugs currently in development.
The argument is that pancreatic cancer has lagged behind other cancers in treatment diversity precisely because the Kras problem seemed intractable. Once that wall falls, the whole pipeline logic changes. Other cancers like breast and lung cancer have benefited from a wide menu of chemotherapy alternatives developed over years. Pancreatic cancer never got that menu. It might finally be getting one.
The 13% five-year survival rate isn't going to jump overnight. But going from 'undruggable' to 'approved daily pill that nearly doubles survival' in the space of one news cycle is a sentence scientists in this field would not have written five years ago.
The Dingo Take
You are supposed to believe, based on years of watching the American healthcare system operate, that breakthroughs like this happen in a clean, linear way. They do not. This one required a company betting heavily on an approach most of the industry had written off, an FDA willing to move fast when the evidence demanded it, and patients in a trial who were already out of options agreeing to try something nobody had ever tried before. All of that has to work at the same time. Usually it doesn't.
It's also worth sitting with what the baseline looked like before Wednesday. More than 52,000 Americans die of pancreatic cancer every year. The mutation driving most of those deaths was identified long ago and promptly declared impossible to target. Patients were told, implicitly, that medicine had seen the thing killing them and couldn't reach it. That is an enormously bleak thing to be told by the medical establishment, and it was true for a very long time.
Now it's not. That matters regardless of what else is happening in the world, regardless of who is running what agency, regardless of the endless daily churn of catastrophic news. Sometimes science actually wins. The pill is called Rasonque, it's a daily tablet, and it nearly doubles how long people with one of the deadliest cancers on earth get to stay alive. File that one somewhere you can find it on a bad day.
Comments